JP2023528895A5 - - Google Patents
Info
- Publication number
- JP2023528895A5 JP2023528895A5 JP2022574675A JP2022574675A JP2023528895A5 JP 2023528895 A5 JP2023528895 A5 JP 2023528895A5 JP 2022574675 A JP2022574675 A JP 2022574675A JP 2022574675 A JP2022574675 A JP 2022574675A JP 2023528895 A5 JP2023528895 A5 JP 2023528895A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- approximately
- treatment
- determined
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025082998A JP2025122066A (ja) | 2020-06-05 | 2025-05-19 | 結節性硬化症の治療の方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063035313P | 2020-06-05 | 2020-06-05 | |
| US63/035,313 | 2020-06-05 | ||
| PCT/EP2021/065075 WO2021245281A1 (en) | 2020-06-05 | 2021-06-04 | Methods of treatment of tuberous sclerosis complex |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025082998A Division JP2025122066A (ja) | 2020-06-05 | 2025-05-19 | 結節性硬化症の治療の方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023528895A JP2023528895A (ja) | 2023-07-06 |
| JP2023528895A5 true JP2023528895A5 (enExample) | 2024-06-13 |
Family
ID=76325558
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022574675A Pending JP2023528895A (ja) | 2020-06-05 | 2021-06-04 | 結節性硬化症の治療の方法 |
| JP2025082998A Pending JP2025122066A (ja) | 2020-06-05 | 2025-05-19 | 結節性硬化症の治療の方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025082998A Pending JP2025122066A (ja) | 2020-06-05 | 2025-05-19 | 結節性硬化症の治療の方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11684613B2 (enExample) |
| EP (1) | EP4161512A1 (enExample) |
| JP (2) | JP2023528895A (enExample) |
| KR (2) | KR20230027145A (enExample) |
| CN (1) | CN116056701A (enExample) |
| AU (1) | AU2021285273A1 (enExample) |
| BR (1) | BR112022024760A2 (enExample) |
| CA (1) | CA3180794A1 (enExample) |
| CL (1) | CL2022003435A1 (enExample) |
| IL (2) | IL322310A (enExample) |
| MX (1) | MX2022015407A (enExample) |
| PH (1) | PH12023550016A1 (enExample) |
| WO (1) | WO2021245281A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022015407A (es) * | 2020-06-05 | 2023-05-16 | Noema Pharma Ag | Metodos de tratamiento del complejo de esclerosis tuberosa. |
| CN120641098A (zh) * | 2023-02-02 | 2025-09-12 | 诺埃玛制药公司 | Dravet综合征的治疗方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4508560A (en) | 1981-11-11 | 1985-04-02 | Ciba Geigy Corporation | Certain pyridylacetylene compounds, compositions containing same and herbicidal methods of use |
| CN100548299C (zh) | 2001-01-05 | 2009-10-14 | 伊莱利利公司 | 兴奋性氨基酸受体拮抗剂 |
| TWI292318B (en) | 2003-03-10 | 2008-01-11 | Hoffmann La Roche | Imidazol-4-yl-ethynyl-pyridine derivatives |
| UA80888C2 (en) * | 2003-06-05 | 2007-11-12 | Hoffmann La Roche | Imidazole derivatives as glutmate receptor antagonists |
| HRP20080363T3 (hr) | 2004-06-01 | 2008-09-30 | F. Hoffmann - La Roche Ag | Piridin-4-il-etinil-imidazoli i pirazoli kao antagonisti mglu5 receptora |
| EP1756086B1 (en) | 2004-06-01 | 2008-06-04 | F.Hoffmann-La Roche Ag | Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as mglu5 receptor antagonists |
| AU2007336369B2 (en) * | 2006-12-21 | 2013-01-17 | F. Hoffmann-La Roche Ag | Polymorphs of a mGluR5 receptor antagonist |
| US8211882B2 (en) | 2008-03-08 | 2012-07-03 | Richard Delarey Wood | Glutamate receptor modulators and therapeutic agents |
| JP2013505262A (ja) | 2009-09-17 | 2013-02-14 | バンダービルト ユニバーシティー | ｍＧｌｕＲ５ネガティブアロステリックモジュレータとしての置換ヘテロアリールアミンカルボキサミド類似体、ならびに、その形成方法および使用方法 |
| US20120039999A1 (en) | 2010-08-11 | 2012-02-16 | Ashish Chatterji | Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists |
| US20120040008A1 (en) * | 2010-08-11 | 2012-02-16 | Ashish Chatterji | Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists |
| CA2845578C (en) | 2011-08-25 | 2016-02-16 | Merck Sharp & Dohme Corp. | Pyrimidine pde10 inhibitors |
| MX2022015407A (es) * | 2020-06-05 | 2023-05-16 | Noema Pharma Ag | Metodos de tratamiento del complejo de esclerosis tuberosa. |
| TWI924682B (zh) | 2020-07-30 | 2026-05-11 | 瑞士商諾埃瑪製藥公司 | 三叉神經痛之治療方法 |
| US20240285637A1 (en) | 2021-07-08 | 2024-08-29 | The Royal Institution For The Advancement Of Learning/Mcgill University | Phosphodiesterase inhibitors for the mitigation of fragile x syndrome symptoms |
| CN119677515A (zh) | 2022-06-15 | 2025-03-21 | 美国政府健康及人类服务部 | 使用代谢型谷氨酸受体5拮抗剂或/和大麻素受体1拮抗剂治疗纤维化疾病 |
| EP4584250A4 (en) | 2022-09-06 | 2026-02-25 | Biohaven Therapeutics Ltd | POLYTHERAPIES INCLUDING METAL CHANNEL ACTIVATORS |
| US20260124188A1 (en) | 2022-10-28 | 2026-05-07 | Orphelion Ab | mGluR receptor antagonists for use in prevention andor treatment of bone marrow lesions (BML) andor osteoporosis, cartilage loss, osteosclerosis and osteitis in a mammal |
| CN120641098A (zh) | 2023-02-02 | 2025-09-12 | 诺埃玛制药公司 | Dravet综合征的治疗方法 |
| EP4680203A1 (en) | 2023-03-14 | 2026-01-21 | Prolevi Bio AB | Compositions for sustained release of poorly soluble active ingredients |
-
2021
- 2021-06-04 MX MX2022015407A patent/MX2022015407A/es unknown
- 2021-06-04 BR BR112022024760A patent/BR112022024760A2/pt unknown
- 2021-06-04 KR KR1020237000370A patent/KR20230027145A/ko not_active Ceased
- 2021-06-04 CN CN202180057592.9A patent/CN116056701A/zh active Pending
- 2021-06-04 CA CA3180794A patent/CA3180794A1/en active Pending
- 2021-06-04 KR KR1020257024877A patent/KR20250116184A/ko active Pending
- 2021-06-04 JP JP2022574675A patent/JP2023528895A/ja active Pending
- 2021-06-04 IL IL322310A patent/IL322310A/en unknown
- 2021-06-04 WO PCT/EP2021/065075 patent/WO2021245281A1/en not_active Ceased
- 2021-06-04 PH PH1/2023/550016A patent/PH12023550016A1/en unknown
- 2021-06-04 EP EP21730918.6A patent/EP4161512A1/en active Pending
- 2021-06-04 AU AU2021285273A patent/AU2021285273A1/en active Pending
- 2021-06-04 IL IL298709A patent/IL298709A/en unknown
-
2022
- 2022-12-02 US US18/061,239 patent/US11684613B2/en active Active
- 2022-12-05 CL CL2022003435A patent/CL2022003435A1/es unknown
-
2023
- 2023-05-11 US US18/315,723 patent/US11998535B2/en active Active
-
2024
- 2024-04-22 US US18/641,640 patent/US12702661B2/en active Active
-
2025
- 2025-05-19 JP JP2025082998A patent/JP2025122066A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2261234T3 (es) | Metabolitos de bupropion y metodos de sintesis y uso. | |
| CN108367005B (zh) | 包含酪氨酸蛋白激酶抑制剂的剂型组合物 | |
| EP2573070B1 (en) | Crystal form of (s)-4-hydroxy-2-oxo-1-pyrrolidine acetamide, preparation method and use thereof | |
| EP3149000B1 (en) | Crystalline tosylate salt of a pi3k delta selective inhibitor for use in pharmaceutical formulations | |
| US11654113B2 (en) | Modified release formulations and uses thereof | |
| FI3856341T3 (fi) | (s)-1-(4-fluorifenyyli)-1-(2-(4-(6-(1-metyyli-1h-pyratsol-4-yyli)pyrrolo[2,1-f][1,2,4]triatsin-4-yyli)piperatsinyyli)pyrimidin-5-yyli)etaani-1-amiinin kidemuotoja ja valmistusmenetelmiä | |
| JP2021505575A (ja) | 非ラセミ混合物およびその使用 | |
| JP2025122066A (ja) | 結節性硬化症の治療の方法 | |
| JP2023540849A5 (enExample) | ||
| RU2247561C1 (ru) | Комбинированная фармацевтическая композиция с противотуберкулёзным действием | |
| HK40064212A (en) | Modified release formulations and uses thereof | |
| TW202237084A (zh) | 修飾釋放調配物及其用途 | |
| HK40059863A (en) | Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase | |
| HK1258699B (en) | Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase | |
| HK1236026B (en) | Crystalline tosylate salt of a pi3k delta selective inhibitor for use in pharmaceutical formulations | |
| WO2010145800A1 (en) | Salts of tramadol and diflunisal and their crystal form in the treatment of pain |